{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:04Z","timestamp":1761630844665},"reference-count":35,"publisher":"Instituto Nacional de Salud Publica","issue":"6, nov-dic","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Salud Publica Mex"],"abstract":"<jats:p>Objetivos. Discutir el c\u00e1ncer cervicouterino (CC), el virus del papiloma humano (VPH), el programa de control del CC y proponer alternativas para Chile.\u00a0Material y m\u00e9todos. Se analiza el programa nacional del CC 1966-2015 y la gu\u00eda cl\u00ednica 2015-2020, la prevalencia de VPH en mujeres y en casos de CC; la infecci\u00f3n y serolog\u00eda de VPH; la autotoma; la precisi\u00f3n y rentabilidad del tamizaje con VPH contra el Papanicolaou y las opciones de triaje en VPH AR positivas.\u00a0Resultados. En Chile mueren 600 mujeres (principalmente de bajos recursos) al a\u00f1o por CC. La cobertura del Papanicolaou es &lt; 70%, sensibilidad muy inferior al test de VPH, por lo que el cambio es rentable. Desde 2015 se vacuna contra VPH a ni\u00f1as menores de 13 a\u00f1os.\u00a0Conclusiones. Las condiciones t\u00e9cnicas y econ\u00f3micas existen en Chile para lograr una mejor\u00eda sustancial del CC: se sugiere el reemplazo del Papanicolaou por el examen de VPH; tamizaje cada cinco a\u00f1os con opci\u00f3n de autotoma; triaje con base en la tipificaci\u00f3n de VPH 16\/18 o Papanicolaou.<\/jats:p>","DOI":"10.21149\/8577","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T20:07:07Z","timestamp":1540584427000},"page":"713","source":"Crossref","is-referenced-by-count":4,"title":["Nuevas estrategias de prevenci\u00f3n y control de c\u00e1ncer de cuello uterino en Chile"],"prefix":"10.21149","volume":"60","author":[{"given":"Catterina","family":"Ferreccio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8786","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Murillo R, Herrero R, Sierra MS, Forman D. Cervical cancer in Central and South America: Burden of disease and status of disease control. Cancer Epidemiol. 2016;44(supl 1):S121-30. https:\/\/doi.org\/10.1016\/j.canep.2016.07.015","DOI":"10.1016\/j.canep.2016.07.015"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Ferreccio C, Barriga MI, Lagos M, Ib\u00e1-ez C, Poggi H, Gonz\u00e1lez F, et al. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. Int J Cancer. 2013;132(4):916-23. https:\/\/doi.org\/10.1002\/ijc.27662. Fe de erratas en: Int J Cancer. 2013;133(2):E1.","DOI":"10.1002\/ijc.27662"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Sep\u00falveda C, Prado R. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Cancer Detect Prev. 2005;29(5):405-11. https:\/\/doi.org\/10.1016\/j.cdp.2005.07.001","DOI":"10.1016\/j.cdp.2005.07.001"},{"key":"ref3","unstructured":"1. Ministerio de Salud de Chile. Porcentaje de cobertura de mujeres beneficiarias de 25 a 64 a-os con PAPVigente, por Servicio de Salud, 2010- 2011. Santiago: Minsal. Disponible en http:\/\/www.deis.cl\/wp-content\/uploads\/2013\/05\/CoberturaPAPOficial_SS2010_2011.pdf"},{"key":"ref4","unstructured":"2. Ministerio de Desarrollo Social. Santiago: Encuesta de Caracterizaci\u00f3n Socioecon\u00f3mica Nacional (CASEN) 2016. [Internet] [aproximadamente 4 pantallas]. Chile: Mindes, c2018- [citado febrero 4, 2018]. Disponible en: http:\/\/observatorio.ministeriodesarrollosocial.gob.cl\/casenmultidimensional\/casen\/casen_2015.php"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1055-9965.2271.13.12","article-title":"Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile.","volume":"13","author":"Ferreccio","year":"2004","unstructured":"6. Ferreccio C, Prado RB, Luzoro AV,Ampuero SL, Snijders PJ, Meijer CJ, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev.2004;13(12):2271-6.","journal-title":"Cancer Epidemiol Biomarkers Prev","ISSN":"http:\/\/id.crossref.org\/issn\/1055-9965","issn-type":"print"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/1097-0215(20010201)91:3<412::AID-IJC1071>3.0.CO;2-M","article-title":"Epidemiology of HPV infection among Mexican women with normal cervical cytology.","volume":"91","author":"Lazcano-Ponce","year":"2001","unstructured":"7. Lazcano-Ponce E, Herrero R, Mu-oz N, Cruz A, Shah KV,Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001;91:412-20. https:\/\/doi.org\/10.1002\/1097-0215(20010201)91:3<412:AID-IJC1071>3.0.CO;2-M","journal-title":"Int J Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0020-7136","issn-type":"print"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92(6):464-74. https:\/\/doi.org\/10.1093\/jnci\/92.6.464","DOI":"10.1093\/jnci\/92.6.464"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Molano M, Posso H,Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, HPV Study Group. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer.2002;87(3):324-33. https:\/\/doi.org\/10.1038\/sj.bjc.6600442","DOI":"10.1038\/sj.bjc.6600442"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Ferreccio C, Corval\u00e1n A, Margozzini P,Viviani P, Gonz\u00e1lez C,Aguilera X, et al. Baseline assessment of prevalence and geographical distribution of HPV types in Chile using self-collected vaginal samples. BMC Public Health. 2008;8:78. https:\/\/doi.org\/10.1186\/1471-2458-8-78","DOI":"10.1186\/1471-2458-8-78"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Castro FA, Dominguez A, Puschel K,Van DeWyngardV, Snijders PJ, Franceschi S, et al. Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile. BMC Infect Dis. 2014;14:361. https:\/\/doi.org\/10.1186\/1471-2334-14-361","DOI":"10.1186\/1471-2334-14-361"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Ferreccio C,Van DeWyngardV, Olcay F, Dom\u00ednguez MA, Puschel K, Corval\u00e1n AH, et al. High-risk HPV infection after five years in a population-based cohort of Chilean women. Infect Agent Cancer. 2011;6(1):21. https:\/\/doi.org\/10.1186\/1750-9378-6-21","DOI":"10.1186\/1750-9378-6-21"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Roa JC, Garcia P, Gomez J, Fern\u00e1ndezW, Gaete F, Espinoza A, et al. HPV genotyping from invasive cervical cancer in Chile. Int J Gynaecol Obstet. 2009;105(2):150-3. https:\/\/doi.org\/10.1016\/j.ijgo.2008.12.017","DOI":"10.1016\/j.ijgo.2008.12.017"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Terrazas S, Ib\u00e1-ez C, Lagos M, Poggi H, Bra-es J, Barriga MI, et al. Examen de detecci\u00f3n de virus papiloma humano en el tamizaje de c\u00e1ncer cervicouterino en un Servicio de Salud de Santiago, Chile. Rev Med Chil. 2015;143(1):56-62. https:\/\/doi.org\/10.4067\/S0034-98872015000100007","DOI":"10.4067\/S0034-98872015000100007"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. L\u00e9niz-Martelli J,Van DeWyngardV, Lagos M, Barriga MI, Puschel-Illanes K, Ferreccio-Readi C. Detecci\u00f3n precoz del c\u00e1ncer cervicouterino en Chile: tiempo para el cambio. Rev Med Chil. 2014;142(8):1047-55. https:\/\/doi.org\/10.4067\/S0034-98872014000800012","DOI":"10.4067\/S0034-98872014000800012"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Lagos M,Van DeWyngardV, Poggi H, Cook P, Viviani P, Barriga MI, et al.HPV16\/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. Infect Agent Cancer. 2015;10:43. https:\/\/doi.org\/10.1186\/s13027-015-0038-5","DOI":"10.1186\/s13027-015-0038-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Benoy IH, Broeck DV, Ruymbeke MJ, Sahebali S,Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2 by cytology screening.Am J Obstet Gynecol. 2011;205(6):569.e1-7. https:\/\/doi.org\/10.1016\/j.ajog.2011.06.101","DOI":"10.1016\/j.ajog.2011.06.101"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Arrossi S, Ramos S, Straw C,Thouyaret L, Orellana L. HPV testing: a mixed-method approach to understand why women prefer self-collection in a middle-income country. BMC Public Health. 2016;16:832. https:\/\/doi.org\/10.1186\/s12889-016-3474-2","DOI":"10.1186\/s12889-016-3474-2"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. L\u00e9niz J, Barriga MI, Lagos M, Ib\u00e1-ez C, Puschel K, Ferreccio C. HPV vaginal self-sampling among women non-adherent to Papanicolaou screening in Chile. Salud Publica Mex. 2013;55(2):162-9. https:\/\/doi.org\/10.1590\/S0036-36342013000200007","DOI":"10.1590\/S0036-36342013000200007"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Franco-Figueira S, Cachoeira CV, Souza FH, Kano BY, Silva M, Poulios N. Cost-effectiveness analysis for cervical cancer screening using Hpv Tests in Chile.Value Health. 2015;18(7):A805-6. https:\/\/doi.org\/10.1016\/j.jval.2015.09.077","DOI":"10.1016\/j.jval.2015.09.077"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Franco-Figueira S, Cachoeira CV, Souza FH, Kano BY, Silva M, Poulios N. Budget Impact model for cervical cancer screening using Hpv Tests in Chile.Value Health. 2015;18(7):A858. https:\/\/doi.org\/10.1016\/j.jval.2015.09.474","DOI":"10.1016\/j.jval.2015.09.474"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: salud p\u00fablica de m\u00e9xico \/ vol. 60, no. 6, noviembre-diciembre de 2018 721 offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134(9):2223-30. https:\/\/doi.org\/10.1002\/ijc.28545","DOI":"10.1002\/ijc.28545"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, et al.The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomized trial cohort through three screening rounds. Health Technol Assess. 2014;18(23):1-196. https:\/\/doi.org\/10.3310\/hta18230","DOI":"10.3310\/hta18230"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M. Cervical cancer screening in partly HPV vaccinated cohorts\u2013 A cost-effectiveness analysis. PLoS One. 2016;11(1):e0145548. https:\/\/doi.org\/10.1371\/journal.pone.0145548","DOI":"10.1371\/journal.pone.0145548"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Chow IH,Tang CH,You SL, Liao CH, Chu TY, Chen CJ, et al. Costeffectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer. 2010;103(12):1773-82. https:\/\/doi.org\/10.1038\/sj.bjc.6605974","DOI":"10.1038\/sj.bjc.6605974"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"5. Balasubramanian A, Kulasingam SL, Baer A, Hughes JP, Myers ER, Mao C, et al.Accuracy and cost-effectiveness of cervical cancer screening byhigh-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis. 2010;14(3):185-95. https:\/\/doi.org\/10.1097\/ LGT.0b013e3181cd6d36","DOI":"10.1097\/LGT.0b013e3181cd6d36"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.Valdez M, Jeronimo J, Bansil P, QiaoYL, Zhao FH, ChenW, et al. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china. Int J Cancer. 2016;138:1453-61. https:\/\/doi.org\/10.1002\/ijc.29877","DOI":"10.1002\/ijc.29877"},{"key":"ref27","unstructured":"6. Ministerio de Salud de Chile. Gu\u00eda Cl\u00ednica AUGE. C\u00e1ncer Cervicouterino (CaCu). Santiago: Minsal, 2015. Disponible en: http:\/\/web.minsal.cl\/wp-content\/uploads\/2015\/09\/GPC-CaCU.pdf"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Balanda M, Quiero A,Vergara N, Espinoza G, Mart\u00edn HS, Rojas G, Ram\u00edrez E. Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014-2015. Med Microbiol Immunol. 2016;205(6):585-94. https:\/\/doi.org\/10.1007\/s00430-016-0473-y","DOI":"10.1007\/s00430-016-0473-y"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. DjemliA,Khetani K, Case BW,Auger M. Correlation of cytotechnologists' parameters with their performance in rapid prescreening of Papanicolaou smears. Cancer. 2006;108(5):306-10. https:\/\/doi.org\/10.1002\/cncr.22166","DOI":"10.1002\/cncr.22166"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Jeronimo J, Bansil P, Lim J, Peck R, Paul P, START-UP Study Group, et al.A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer. 2014;24(3):576-85. https:\/\/doi.org\/10.1097\/IGC.0000000000000084","DOI":"10.1097\/IGC.0000000000000084"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. L\u00f3pez-Alegr\u00eda F, Lorenzi DR, Poblete OQ. Follow-up of women with inadequate Pap smears: a prospective cohort study. Sao Paulo Med J. 2015;133(1):20-7. https:\/\/doi.org\/10.1590\/1516-3180.2013.7070004","DOI":"10.1590\/1516-3180.2013.7070004"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Naber SK, de Kok IM, Matthijsse SM, van Ballegooijen M.The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control. 2016;27(4):569-81. https:\/\/doi.org\/10.1007\/s10552-016-0732-7","DOI":"10.1007\/s10552-016-0732-7"},{"key":"ref33","unstructured":"7. Comisi\u00f3n Nacional deVacunas y Estrategias deVacunaci\u00f3n (CAVEI). Vacuna contra el virus del papiloma humano (VPH). Santiago de Chile: Minsal, 2012 [citado febrero 4, 2018]. Disponible en: http:\/\/www.minsal.cl\/sites\/default\/files\/files\/VPHCAVEIRecomendacionOctubre2012.pdf"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Schiffman M. Cervical cancer screening: Epidemiology as the necessary but not sufficient basis of public health practice. Prev Med. 2017;98:3-4. https:\/\/doi.org\/10.1016\/j.ypmed.2016.12.028","DOI":"10.1016\/j.ypmed.2016.12.028"}],"container-title":["Salud P\u00fablica de M\u00e9xico"],"original-title":[],"link":[{"URL":"http:\/\/www.saludpublica.mx\/index.php\/spm\/article\/viewFile\/8577\/11649","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.saludpublica.mx\/index.php\/spm\/article\/viewFile\/8577\/11649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T19:32:59Z","timestamp":1662319979000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.saludpublica.mx\/index.php\/spm\/article\/view\/8577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":35,"journal-issue":{"issue":"6, nov-dic","published-online":{"date-parts":[[2018,12,13]]}},"URL":"https:\/\/doi.org\/10.21149\/8577","relation":{},"ISSN":["1606-7916","0036-3634"],"issn-type":[{"value":"1606-7916","type":"electronic"},{"value":"0036-3634","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}